TrialThe oncologist2018

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

Xiao X Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.